Charles Swanton
Professor
Healthcare
Bio Soja Group
Congo
Biography
Charlie Swanton is a Royal Society Napier Professor of Cancer and consultant thoracic oncologist at UCL Hospitals and group Leader of the Translational Cancer Therapeutics laboratory at Cancer Research UK (CRUK) and the Francis Crick Institute. He is a world leader in the understanding of genomic diversity within cancers (intratumour heterogeneity) and molecular mechanisms driving cancer branched evolution. He has published over 130 papers and is the recipient of a number of awards in recognition of his research. He is the co-director of the CRUK Lung Cancer Centre of Excellence and an appointed Fellow of the European Academy of Cancer Sciences (2014) and a Fellow of the Academy of Medical Sciences (2015). He is chief investigator of the UK cancer evolution program TRACERx. He has unparalleled experience in cell biology, bio-informatics and the development of a sequencing pipeline for the prediction and annotation of neo-antigens. Charlie holds an MB BS and first class honors degree in Cell Biology and Immunology from UCL medical schools and Ph.D. from the Imperial Cancer Research Fund.
Research Interest
Charlie Swanton is a Royal Society Napier Professor of Cancer and consultant thoracic oncologist at UCL Hospitals and group Leader of the Translational Cancer Therapeutics laboratory at Cancer Research UK (CRUK) and the Francis Crick Institute. He is a world leader in the understanding of genomic diversity within cancers (intratumour heterogeneity) and molecular mechanisms driving cancer branched evolution. He has published over 130 papers and is the recipient of a number of awards in recognition of his research. He is the co-director of the CRUK Lung Cancer Centre of Excellence and an appointed Fellow of the European Academy of Cancer Sciences (2014) and a Fellow of the Academy of Medical Sciences (2015). He is chief investigator of the UK cancer evolution program TRACERx. He has unparalleled experience in cell biology, bio-informatics and the development of a sequencing pipeline for the prediction and annotation of neo-antigens. Charlie holds an MB BS and first class honors degree in Cell Biology and Immunology from UCL medical schools and Ph.D. from the Imperial Cancer Research Fund.
